Manufacturers are likely to focus on developing biosimilars to innovators biologics with annual sales approaching $1 billion or more in order to recoup the high cost of getting to market, according to an analysis by Matrix Global Advisors health economist Alex Brill.
Brill’s analysis is based on an economic model intended to show the level of sales needed for a biosimilar to break even after development and compliance costs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?